Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer

被引：0
|
作者：
Bauer, Smadar
Saad, Akram
Greenhouse, Inbal
Rapoport, Anna Ruth
Shahar, Shir
Barnatan, Tania
Satchi-Fainaro, Ronit
Shapira-Frommer, Ronnie
机构：
[1] Sheba Med Ctr, Ramat Gan, Israel
[2] Tel Aviv Univ, Dept Physiol & Pharmacol, Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    Aghajanian, Carol
    Blessing, John A.
    Darcy, Kathleen M.
    Reid, Gary
    DeGeest, Koen
    Rubin, Stephen C.
    Mannel, Robert S.
    Rotmensch, Jacob
    Schilder, Russell J.
    Riordan, William
    GYNECOLOGIC ONCOLOGY, 2009, 115 (02) : 215 - 220
  • [32] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    S McMeekin
    R Patel
    C Verschraegen
    P Celano
    J Burke
    S Plaxe
    P Ghatage
    M Giurescu
    C Stredder
    Y Wang
    T Schmelter
    British Journal of Cancer, 2012, 106 : 70 - 76
  • [33] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Koensgen, Dominique
    Stengel, Dirk
    Belau, Antje
    Klare, Peter
    Oskay-Oezcelik, Guelten
    Steck, Thomas
    Camara, Oumar
    Mustea, Alexander
    Sommer, Harald
    Coumbos, Alexandra
    Bogenrieder, Thomas
    Lichtenegger, Werner
    Sehouli, Jalid
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 393 - 400
  • [34] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J., II
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    Schmelter, T.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 70 - 76
  • [35] Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Dominique Koensgen
    Dirk Stengel
    Antje Belau
    Peter Klare
    Guelten Oskay-Oezcelik
    Thomas Steck
    Oumar Camara
    Alexander Mustea
    Harald Sommer
    Alexandra Coumbos
    Thomas Bogenrieder
    Werner Lichtenegger
    Jalid Sehouli
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 393 - 400
  • [36] A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma
    Rodriguez, M
    Method, MW
    Lewandowski, G
    Vaccarello, L
    Ansari, RH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 464S - 464S
  • [37] A PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB IN RECURRENT OR PERSISTENT CLEAR CELL CARCINOMA OF THE OVARY
    Lee, Elizabeth
    Tayob, Nabihah
    Rimel, Bj
    Hendrickson, Andrea Wahner
    Nixon, Andrew
    Matulonis, Ursula
    Liu, Joyce
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A238 - A238
  • [38] A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
    Lee, Yong Jae
    Lim, Myong Cheol
    Kim, Byoung Gie
    Ngoi, Natalie Yl
    Choi, Chel Hun
    Park, Sang Yoon
    Tan, David S. P.
    Go, Yunjung
    Lee, Jung Yun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 7
  • [39] PHASE 2 TRIAL OF DOSE DENSE (WEEKLY) PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R.
    Dorman, D.
    Lee, J.
    Apte, S.
    Chon, H.
    Shahzad, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 877 - 877
  • [40] The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer
    Barbi, Mali
    Lee, Chung-Shien
    Rahman, Husneara
    Cheng, Kit
    Jean, Lee
    John, Veena S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345